Synthesis and Oral Hypoglycemic Activity of Some New Sulphonyl Linkage Thiazolidine-2,4-diones
Abstract
Type 2 diabetes mellitus and its complications, decreases the quality of life in diabetic patients. Thiazolidine-2,4-diones are found to be better insulin sensitizing agents, acting on peroxisome proliferator activated receptor-γ (PPAR-γ) and decrease blood glucose level in diabetic patient. Therefore, in the present work, we synthesized 5-[4-(substituted) sulphonylbenzylidene]thiazolidine-2,4-diones and evaluated for their oral hypoglycemic activity. The synthesized compounds were further studied for their find out interactions with 2PRG protein with the help of docking score and also find out their predicated ED25 values. The results of synthesized compounds were showed significant decrease in blood glucose level as compared to positive control group. All synthesized compounds have shown good hydrogen bond interactions with 2PRG protein, docking score and predicted ED25 value as compared with reference drug, pioglitazone and rosiglitazone, respectively. Thus, sulphonyl linked thiazolidine-2,4-diones may be used as promising oral hypoglycemic agent.
Keywords:
Type 2 Diabetes Mellitus, Thiazolidine-2,4-diones, Peroxisome Proliferator Activated Receptor-γ, Oral Hypoglycemic Activity, Docking Score, Predicated ED25 valueDOI
https://doi.org/10.25004/IJPSDR.2020.120603References
Al-Najjar BO, Wahab HA, Tengku Muhammad TS, Shu-Chien, AC, Ahmad Noruddin NA, Taha MO. Discovery of New Nanomolar Peroxisome Proliferator-Activated Receptor-γ Activators Via Elaborate Ligand-Based Modeling. Eur J Med Chem. 2011; 46: 2513-2529.
Rikimaru K, Wakabayashi T, Abe H, Imoto H, Maekawa T, Ujikawa O, Murase K, Matsuo T, Matsumoto M, Nomura C, Tsuge H, Arimura N, Kawakami K, Sakamoto J, Funami M, Mol CD, Snell GP, Bragstad KA, Sang B-I, Dougan DR, Tanaka T, Katayama N, Horiguchi Y, Momose Y. A New Class of Non-Thiazolidinedione, Non-Carboxylic-Acid-Based Highly Selective Peroxisome Proliferator-Activated Receptor (PPAR)γ Agonists: Design and Synthesis of Benzylpyrazole Acylsulfonamides. Bioorg Med Chem. 2012; 20: 714-733.
Lohray BB, Bhushan V, Rao BP, Madhavan GR, Murali N, Rao KN, Reddy AK, Rajesh BM, Reddy PG, Chakrabarti R, Jajoo H, Vikramadithyan R, Rajagopalan R, Mamidi RNVS, Subramaniam S. Novel Euglycemic and Hypolipidemic Agents.1. J Med Chem. 1998; 41:1619-1630.
Xu Y, Rito CJ, Etgen GJ, Ardecky RJ, Bean JS, Bensch WR, Bosley JR, Broderick CL, Brooks DA, Dominianni SJ, Hahn PJ, Liu S, Mais DE, Montrose-Rafizadeh C, Ogilvie KM, Oldham BA, Peters M, Rungta DK, Shuker AJ, Stephenson GA, Tripp AE, Wilson SB, Winneroski LL, Zink R, Kauffman RF, McCarthy JR. Design and Synthesis of α-Aryloxy-α-Methylhydrocinnamic Acids: A Novel Class of Dual Peroxisome Proliferator-Activated Receptor α/γ Agonists. J Med Chem. 2004; 47:2422-2425.
Havale SH, Pal M. Medicinal Chemistry Approaches to the Inhibition of Dipeptidyl Peptidase-4 for the Treatment of Type 2 Diabetes. Bioorg Med Chem. 2009; 17:1783-1802.
Han HO, Kim SH, Kim K-H, Hur G-C, Yim HJ, Chung HK, Woo SH, Koo KD, Lee C-S, Koh JS, Kim GT. Design and Synthesis of Oxime Ethers of α-Acyl-β-Phenylpropanoic Acids as PPAR Dual Agonists. Bioorg Med Chem Lett. 2007; 17: 937-941.
Kumar BRP, Soni M, Kumar SS, Singh K, Patil M, Nasir Baig RB, Adhikary L. Synthesis, Glucose Uptake Activity and Structure-Activity Relationships of Some Novel Glitazones Incorporated with Glycine, Aromatic and Alicyclic Amine Moieties via Two Carbon Acyl Linker. Eur J Med Chem. 2011; 46:835-844.
Dumbare M, Kawale L, Nade V, Deshmukh R. Thiazolidine-2,4-diones: An Update Review of Antidiabetic Agents. Int Res J Pharm. 2017; 8(12):12-29.
Elte J W F , B licklé J F . R eview A rticle Thiazolidinediones for the Treatment of Type 2 Diabetes. European Journal of Internal Medicine 2007; 18: 18–25.
Chiarelli F, Marzio D D. Peroxisome Proliferator-Activated Receptor-γ Agonists and Diabetes: Current Evidence and Future Perspectives. Vascular health and risk management. 2008: 4(2): 297-304.
Dumbare M, Kawale L, Nade V, Deshmukh R. Review Article on Thiazolidine-2,4-Diones an Insulin Sensitizing Agents. Inter J of Pharmacotherapy. 2018; 8(2):39-53.
Roy A, Dumbare MR, Patil TD, Bhanwase AS, Deshmukh RD. Synthesis, Biological Evaluation and Molecular Modeling Studies of 5-[4-(Substituted)Benzylidene or Benzyl]Thiazolidine-2,4-dione with Oral Antihyperglycemic Activity. Int J Pharm Tech Res. 2013; 5(4):1882-1895.
Hulin B, Clark DA, Goldstein SW, McDermott RE, Dambek PJ, Kappeler WH, Lamphere CH, Lewis DM, Rizzi JP. Novel Thiazolidine-2,4-diones as Potent Euglycemic Agents. J Med Chem. 1992; 35(10):1853-1864.
Nagarchi K, Ahmed S, Sabus A, Saheb SH. Effect of Streptozotocin on Glucose Levels in Albino Wister Rat. J Pharm Sci Res. 2015; 7: 67- 69.
Roy A, Dumbare MR, Harak SS, Najeeb MZ, Deshmukh RD. Synthesis, Molecular Docking Studies and Biological Evaluation of 5-[4-(Substituted)Benzylidene or Benzyl]Thiazolidine-2,4-dione with Their Oral Hypoglycemic Activity. Int Res J Pharm. 2013; 4:151-157.
Kulkarni SS, Gediya LK, Kulkarni V M. Three-Dimensional Quantitative Structure Activity Relationships (3-D-QSAR) of Antihyperglycemic Agents. Bioorg Med Chem.1999; 7: 1475-1485.
Published
Abstract Display: 443 
PDF Downloads: 527 
